Evaluation of the Caveolin-1 expressions in uterine cervical carcinomas

Aim: Caveolin-1 (Cav-1) is an important regulator of cellular processes and it involves several biological and metabolic functions, including cell growth, apoptosis, angiogenesis, and also carcinogenesis. This retrospective study was designed to evaluate the differences of tissue expressions of Cav-1 in a spectrum of cervical neoplasms. Materials and Methods: Tissue expression of Cav-1 was studied in a total of 107 formalin-fixed, paraffin-embedded uterine cervical tumors specimens and its association with different clinicopathologic parameters was evaluated. Results: In this series, there were 30 low- and 29 high-grade cervical intraepithelial neoplasms, 27 squamous cell carcinomas (SCCs), 15 adenosquamous carcinomas (ASCs), and six adenocarcinomas (ACs). Epithelial Cav-1 expression was determined in most SCCs, while it was negative in all ACs and most ASCs (p < 0.001). Statistically it was determined that the expression of stromal Cav-1 was significantly upregulated in invasive carcinomas when compared with non-invasive squamous cell carcinomas (p < 0.001), and this finding was inconsistent with literature. Conclusions: The present findings demonstrated a link between epithelial Cav-1 expression and the squamous differentiation of uterine neoplasms, as well as the relationship between invasion and stromal Cav-1 expression. Therefore it may be suggested that Cav-1 may play a role in the pathogenesis of cervical SCCs.

Uterine cervix; Caveolin-1 (Cav-1); Squamous cell carcinomas (SCC); Adenosquamous carcinoma; Adenocarcinoma.

[1] Wang S.M., Qiao Y.L.: “Implementation of cervical cancer screening and prevention in China—challenges and reality”. Jpn. J. Clin. Oncol., 2015, 45, 7.

[2] Lida K., Nakayama K., Rahman M.T., Rahman M., Ishikawa M., Katagiri A., et al.: “EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target”. Br. J. Cancer, 2011, 105, 420.

[3] Yan M., Zhang Y.N., He J.H., Huang H.: “Prognosis analysis of 83 cases of cervical adenosquamous carcinoma”. Ai Zheng, 2008, 27, 242. [Article in Chinese]

[4] Longatto-Filho A., Pinheiro C., Martinho O., Moreira M.A.R., Ribeiro L.F.J., Queiroz G.S., et al.: “Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma”. BMC Cancer, 2009, 9, 212.

[5] Contag S.A., Gostout B.S., Clayton A.C., Dixon M.H., McGovern R.M., Calhoun E.S.: “Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix”. Gynecol. Oncol., 2004, 95, 610.

[6] Kurman R.J., Ellenson L.H., Ronnett B.M.: “Bleustein’s pathology of the female genital tract”. 6thed. Springer: New York, 2011, 286.

[7] Kaidar-Person O., Yosefia S., Abdah-Bortnyak R.: “Response of adenocarcinoma of the uterine cervix to chemoradiotherapy”. Oncol. Lett., 2015, 9, 2791.

[8] Sáinz-Jaspeado M., Martin-Liberal J., Lagares-Tena L., Mateo- Lozano S., Garcia del Muro X., Tirado O.M.: “Caveolin-1 in sarcomas: friend or foe?” Oncotarget, 2011, 2, 305.

[9] Steffens S., Schrader A.J., Blasig H., Vetter G., Eggers H., Tränkenschuh W., et al.: “Caveolin 1 protein expression in renal cell carcinoma predicts survival”. BMC Urol., 2011, 11, 25.

[10] Tse E.Y., Ko F.C., Tung E.K., Chan L.K., Lee T.K., Ngan E.S., et al.: “Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis”. J. Pathol., 2012, 226, 645.

[11] Barresi V., Cerasoli S., Paioli G., Vitarelli E., Giuffrè G., Guiducci G., et al.: “Caveolin-1 in meningiomas: expression and clinicopathological correlations”. Acta Neuropathol., 2006, 112, 617.

[12] Senetta R., Stella G., Pozzi E., Sturli N., Massi D., Cassoni P.: “Caveolin-1 as a promoter of tumour spreading: when, how, where and why”. J. Cell. Mol. Med., 2013, 17, 325.

[13] Paskaš S., Janković J., Marečko I., Išić Denčić T., Tatić S., Cvejić D., Savin S.: “Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status”. Otolaryngol. Head Neck Surg., 2014, 150, 201.

[14] Max X., Liu L., Nie W., Li Y., Zhang B., Zhang J., Zhou R.: “Prognostic role of caveolin in breast cancer: a meta-analysis”. Breast, 2013, 22, 462.

[15] Wu K.N., Queenan M., Brody J.R., Potoczek M., Sotgia F., Lisanti M.P., Witkiewicz A.K.: “Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival”. Cell Cycle,2011, 10, 4250.

[16] Faggi F., Mitola S., Sorci G., Riuzzi F., Donato R., Codenotti S., et al.: “Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma”. PLoS One, 2014, 9, e84618.

[17] Engelman J.A., Zhang X., Galbiati F., Volonte D., Sotgia F., Pestell R.G., et al.: “Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy”. Am. J. Hum. Genet., 1998, 63, 1578.

[18] Campbell L., Al-Jayyoussi G., Gutteridge R., Gumbleton N., Griffiths R., Gumbleton S., et al.: “Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease”. J. Transl. Med., 2013, 11, 255.

[19] Ayala G., Morello M., Frolov A., You S., Li R., Rosati F., et al.: “Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression” J. Pathol., 2013, 231, 77.

[20] Basu Roy U.K., Henkhaus R.S., Loupakis F., Cremolini C., Gerner E.W., Ignatenko N.A.: “Caveolin-1 is a novel regulator of K-RASdependent migration in colon carcinogenesis”. Int. J. Cancer, 2013, 133, 43.

[21] Li L., Ren C.H., Tahir S.A., Ren C., Thompson T.C.: “Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A”. Mol. Cell. Biol., 2003, 23, 9389.

[22] Goetz J.G., Minguet S., Navarro-Lérida I., Lazcano J.J., Samaniego R., Calvo E., et al.: “Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis”. Cell, 2011, 146, 148.

[23] Sayhan S., Diniz G., Karadeniz T., Ayaz D., Solakoglu Kahraman D., Gokcu M., Tosun Yildirim H.: “Expression of Caveolin-1 in peritumoral stroma is associated with histological grade in ovarian serous tumors”. Ginekol. Pol., 2015, 86, 424.

[24] Rossi S., Poliani P.L., Cominelli M., Bozzato A., Vescovi R., Monti E., Fanzani A.: “Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma”. Eur. J. Cancer, 2011, 47, 761.

[25] Quann K., Gonzales D.M., Mercier I., Wang C., Sotgia F., Pestell R.G., et al.: “Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide”. Cell Cycle, 2013, 12, 1510.

[26] Faggi F., Mitola S., Sorci G., Riuzzi F., Donato R., Codenotti S., et al.: “Phosphocaveolin-1 Enforces Tumor Growth and Chemoresistance in Rhabdomyosarcoma”. PLoS One, 2014, 9, e84618.

[27] Davidson B., Goldberg I., Givant-Horwitz V., Nesland J.M., Berner A., Bryne M., et al.: “Caveolin-1 expression in ovarian carcinoma is MDR1 independent”. Am. J. Clin. Pathol., 2002, 117, 225.

[28] Wiechen K., Diatchenko L., Agoulnik A., Scharff K.M., Schober H., Arlt K., et al.: “Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene”. Am. J. Pathol., 2001, 159, 1635.

[29] Solakoglu Kahraman D., Diniz G., Sayhan S., Ayaz D., Uncel M., Karadeniz T., et al.: “Differences in the ARID-1A expression in squamous and adenosquamous carcinomas in uterine cervix”. APMIS, 2015, 123, 847.